Monument Therapeutics, Cambridge, UK; Cambridge Cognition, Cambridge, UK; School of Psychology, University of Nottingham, Nottingham, UK.
Monument Therapeutics, Cambridge, UK; Cambridge Cognition, Cambridge, UK; Department of Psychiatry, University of Cambridge, Cambridge, UK.
Drug Discov Today. 2021 May;26(5):1111-1114. doi: 10.1016/j.drudis.2021.01.019. Epub 2021 Jan 23.
Inflammation within the central nervous system (CNS; neuroinflammation) is a major contributor to lasting symptoms of traumatic brain injury and stroke, and likely has a casual role Alzheimer's disease (AD) and other neurodegenerative conditions. Therapeutic modulation of the immune processes that initiate and maintain neuroinflammation is of growing scientific interest but neuroinflammatory drug development is hampered by limited reliability and availability of neuroimaging or other biomarkers in humans. Better means of establishing drug efficacy on human neuroinflammation would have great value in accelerating the development of neuroinflammatory compounds for many clinical indications. Here, we discuss the use of postoperative cognitive decline (POCD), which is hypothesised to have a neuroinflammatory basis, as an acute indication to demonstrate the efficacy of novel neuroinflammatory drugs.
中枢神经系统（CNS；神经炎症）内的炎症是导致创伤性脑损伤和中风持续症状的主要原因，并且可能在阿尔茨海默病（AD）和其他神经退行性疾病中起因果作用。治疗性调节启动和维持神经炎症的免疫过程引起了越来越多的科学关注，但神经炎症药物的开发受到人类神经影像学或其他生物标志物的可靠性和可用性有限的阻碍。在人类神经炎症方面建立药物疗效的更好方法将极大地促进针对许多临床适应症的神经炎症化合物的开发。在这里，我们讨论了术后认知障碍（POCD）的使用，POCD 假设具有神经炎症基础，可以作为一种急性指标来证明新型神经炎症药物的疗效。
